Naftifine hydrochloride is a potent allylamine-class antifungal agent widely used in pharmaceutical and fine chemical industries. It acts by inhibiting fungal squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. As a topical antifungal drug, it is formulated into creams, gels, and solutions for treating superficial fungal infections such as tinea corporis, tinea cruris, tinea pedis, and cutaneous candidiasis. It exhibits broad-spectrum activity against dermatophytes, yeasts, and molds, with faster fungicidal action than azole drugs. In pharmaceutical research, it serves as a reference standard for antifungal drug development and quality control. It is also used as a key intermediate in synthesizing other allylamine antifungals. Additionally, it is applied in academic studies to explore fungal lipid metabolism and antifungal resistance mechanisms.

Naftifine hydrochloride is classified as a low-toxicity irritant (GHS07) with hazard statements H302 (harmful if swallowed), H315 (causes skin irritation), H319 (causes serious eye irritation), and H335 (may cause respiratory irritation). Inhalation of dust may trigger nasal/throat irritation, cough, or mild dyspnea; long-term inhalation may cause headache or dizziness. Skin contact often leads to redness, itching, or mild dermatitis due to defatting effects. Eye exposure causes severe stinging, tearing, and conjunctival swelling; prolonged contact may damage corneal epithelium. Ingestion may induce nausea, vomiting, abdominal pain, or diarrhea. Operators must wear nitrile gloves, safety goggles, and dust respirators in well-ventilated areas. In case of contact, rinse skin/eyes with plenty of water for 15 minutes; seek medical aid if irritation persists. Store sealed at 2–8 °C, away from oxidants, heat, and moisture. Dispose of waste per local pharmaceutical waste regulations to avoid environmental contamination.